
CLAIMS

What is claimed is:

1. A compound of the formula:



or a pharmaceutically acceptable salt or hydrate thereof, wherein:



represents a 5-membered heteroaryl ring;

W is $–C(=O)NR_4-$, $–NR_4C(=O)-$ or $–NR_4-NR_4-C(=O)-$;

X is absent or C_1-C_6alkylene that is substituted with from 0 to 4 substituents independently chosen from: (i) hydroxy and –COOH;

(ii) C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_6aminoalkyl, C_2-C_8alkyl ether, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl and phenylC_0-C_2alkyl;

(iii) substituents that are taken together, with any intervening carbon atoms, to form a 3- to 7-membered cycloalkyl or a 4- to 7-membered heterocycloalkyl; and

(iv) substituents that are taken together with R_4 and any intervening atoms to form a 4- to 7-membered heterocycloalkyl;

each of which (ii), (iii) and (iv) is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and 4- to 7-membered heterocycloalkyl;

Y is C_4-C_{12}cycloalkyl that is substituted with from 0 to 6 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl and mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl;

R_2 represents from 0 to 2 substituents independently chosen from halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-

C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

such that R_2 is not an alkoxy or haloalkoxy group if  represents pyrazole or imidazole;

Each R_4 is independently hydrogen, C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_2alkyl or taken together with a substituent of X to form a 4- to 7-membered heterocycloalkyl; and

R_A is a group of the formula -L-A-M, wherein:

L is absent or C_1-C_6alkylene that is optionally modified by the replacement of a carbon-carbon single bond with a double or triple carbon-carbon bond, which alkylene is optionally substituted with oxo, –COOH, $–SO_3H$, $–SO_2NH_2$, $–PO_3H_2$, tetrazole or oxadiazolone;

A is absent or CO, O, NR_6, S, SO, SO_2, $CONR_6$, NR_6CO, (C_4-C_7cycloalkyl)C_0-C_2alkyl, 4- to 7-membered heterocycloalkyl or 5- or 6-membered heteroaryl; wherein R_6 is hydrogen or C_1-C_6alkyl; and

M is:

(i) hydroxy, cyano, amino, aminocarbonyl, aminosulfonyl or –COOH; or

(ii) C_3-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, (4- to 10-membered carbocycle)C_0-C_4alkyl, (4- to 7-membered heterocycle)C_0-C_4alkyl, C_1-C_6alkanoyloxy, C_1-C_6alkanoylamino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, C_1-C_6alkylsulfonyloxy, mono- or di-C_1-C_6alkylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, or mono- or di-(C_1-C_6alkyl)aminocarbonyl; each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl, and 4- to 7-membered heterocycle;

such that:

R_A is not unsubstituted benzyl; and


if  represents pyrazole or imidazole and L is absent, then:


(a) A is not O; and

(b) if A is absent, then M is not unsubstituted or substituted C_1-C_6alkoxy.

2. A compound or salt or hydrate thereof according to claim 1, wherein:

Y is:




or

; and

R_1 represents from 0 to 6 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl and mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl.

3. A compound or salt or hydrate thereof according to claim 1 or claim 2, wherein X is not absent.


4. A compound or salt or hydrate thereof according to any one of claims 1-3, wherein  is pyrazole, thiazole, imidazole, oxazole or thiophene.

5. A compound or salt or hydrate thereof according to claim 4, wherein the compound satisfies the formula:




wherein Z_1, Z_2 and Z_3 are independently N, NH, CH, S or O; such that no more than one of Z_1, Z_2 and Z_3 is chosen from O and S.

6. A compound or salt or hydrate thereof according to claim 5, wherein the compound satisfies the formula:




7. A compound or salt or hydrate thereof according to claim 6, wherein the compound satisfies the formula:




;

wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

8. A compound or salt or hydrate thereof according to claim 5, wherein the compound satisfies the formula:





9. A compound or salt or hydrate thereof according to claim 8, wherein the compound satisfies the formula:



wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.


10. A compound or salt or hydrate thereof according to claim 5, wherein the compound satisfies the formula:



or


wherein R_3 is hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

11. A compound or salt or hydrate thereof according to claim 4, wherein the compound satisfies the formula:




wherein:


Z_4 and Z_5 are independently CH, N, NH, O or S; and


Z_6 is CH, S or O;

such that no more than one of Z_4, Z_5 and Z_6 is chosen from O and S.

12. A compound or salt or hydrate thereof according to claim 11, wherein the compound satisfies the formula:



,


or


;

wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

13. A compound or salt or hydrate thereof according to any one of claims 7, 9, 10, 12 and 13, wherein each R_3 is independently hydrogen, halogen, C_1-C_4alkyl or C_1-C_4haloalkyl.

14. A compound or salt or hydrate thereof according to any one of claims 1-13, wherein R_A is phenylC_0-C_2alkyl, (5- or 6-membered heteroaryl)C_0-C_4alkyl, phenylC_0-C_2alkyl-T- or (5- or 6-membered heteroaryl)C_0-C_4alkyl-T-, wherein T is S or O, each of which is substituted with from 0 to 4 substituents independently chosen from:


(i) oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl and –COOH; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkenylthio, C_2-C_6alkyl ether, (mono- or di-C_1-C_6alkylamino)C_0-C_4alkyl, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, and (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl; each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_4alkyl and C_1-C_4haloalkyl;

such that if 

represents pyrazole or imidazole, then T is not O; and R_A is not unsubstituted benzyl.

15. A compound or salt or hydrate thereof according to claim 14, wherein R_A is (5- or 6-membered heteroaryl)C_0-C_4alkyl that is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl, and 4- to 7-membered heterocycle; wherein the 5- or 6-membered heteroaryl is pyridyl, pyrimidinyl, imidazolyl or chosen from


and

16. A compound or salt or hydrate thereof according to any one of claims 1-13, wherein R_A is C_3-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkoxy, C_1-C_6alkylthio, C_2-C_6alkenylthio, C_2-C_6alkyl ether, C_1-C_6alkoxycarbonyl, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-C_1-C_6alkylaminosulfonyl, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl or (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl-T-, wherein T is S or O; each of which is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, halogen, hydroxy, aminocarbonyl, aminosulfonyl and –COOH; and

(ii) C_1-C_6alkyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6alkylthio, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-C_1-C_6alkylaminocarbonyl, mono- or di-C_1-C_6alkylaminosulfonyl and 4- to 7-membered heterocycle; each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_4alkyl and C_1-C_4haloalkyl;

such that if 

represents pyrazole or imidazole, then R_A is not optionally substituted C_1-C_6alkoxy.

17. A compound or salt or hydrate thereof according to claim 16, wherein R_A is C_3-C_6alkyl, C_2-C_6alkyl ether, C_1-C_4alkoxycarbonyl, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, or (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl; each of which is substituted with from 0 to 4 substituents independently chosen from amino, hydroxy, oxo, aminocarbonyl, aminosulfonyl, C_1-C_6alkyl, C_1-C_6hydroxyalkyl, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)amino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, 4- to 7-membered heterocycloalkyl, and 5- or 6-membered heteroaryl.


18. A compound or salt or hydrate thereof according to claim 17, wherein R_A is C_3-C_6alkyl, C_2-C_6alkyl ether, or mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, each of which is substituted with from 1 to 4 substituents independently chosen from halogen, hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkoxy, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkanoylamino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonyloxy, C_1-C_6alkylsulfonylamino, and 4- to 7-membered heterocycle.

19. A compound or salt or hydrate thereof according to claim 18, wherein R_A is:

(i) C_3-C_6alkyl that is substituted with amino, hydroxy or –COOH; or

(ii) mono- or di-(C_1-C_6alkyl)aminoC_0-C_2alkyl that is substituted with from 0 to 2 substituents independently chosen from hydroxy, oxo, amino, –COOH and C_1-C_4alkylsulfonylamino.

20. A compound or salt or hydrate thereof according to any one of claims 1-13, wherein R_A is a group of the formula:



wherein:

L is absent or C_1-C_6alkylene;



represents a 4- to 7-membered heterocycloalkyl that is optionally fused to phenyl or to a 6-membered heteroaryl; and


R_7 represents from 0 to 4 substituents independently chosen from:

(i) hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl and –COOH;

(ii) C_1-C_6alkyl, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, C_1-C_6alkylsulfonylC_0-C_4alkyl, C_1-C_6alkylsulfonylaminoC_0-C_4alkyl, and 4- to 7-membered heterocycle; each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6alkoxy, mono- or di-(C_1-C_6alkyl)amino, and C_1-C_6alkylsulfonylamino; and

(iii) substituents that are taken together to form a bridge of the Formula $-(CH_2)_q$-P-$(CH_2)_r$-, wherein q and r are independently 0 or 1 and P is CH_2, O, NH or S.

21. A compound or salt or hydrate thereof according to claim 20, wherein R_A is a group of the formula:



wherein:

G is CH or N;

s and t are independently 0, 1, 2, 3 or 4, such that the sum of s and t ranges from 2 to 5; and


R_8 is:







(i) hydrogen, aminocarbonyl, aminosulfonyl or –COOH; or

(ii) C_1-C_6alkyl, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, C_1-C_6alkylsulfonylC_0-C_4alkyl, C_1-C_6alkylsulfonylaminoC_0-C_4alkyl, or 4- to 7-membered heterocycle; each of which is substituted with from 0 to 4 substituents independently chosen from halogen,

hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6alkoxy, mono- or di-(C_1-C_6alkyl)amino, and C_1-C_6alkylsulfonylamino.

22. A compound or salt or hydrate thereof according to claim 20, wherein R_A is








or

;

wherein:

R_9 is: (i) C_1-C_6alkyl that is substituted with –COOH; or (ii) a 5- or 6-membered heteroaryl that is unsubstituted or substituted with 1 or 2 oxo; and

R_{10} represents one substituent chosen from:

(i) –COOH;

(ii) C_1-C_6alkyl that is substituted with –COOH;

(iii) mono- or di-(C_1-C_6alkyl)aminoC_0-C_2alkyl, C_1-C_6alkylsulfonyl and C_1-C_6alkylsulfonylamino; each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, oxo and –COOH; and





(iv) C_1-C_6haloalkylsulfonylamino.





23. A compound or salt or hydrate thereof according to any one of claims 1-22, wherein R_2 represents from 0 to 2 substituents independently chosen from halogen, C_1-C_6alkyl and C_1-C_6haloalkyl.




24. A compound or salt or hydrate thereof according to any one of claims 1-23, wherein X is methylene or ethylene, each of which is substituted with from 0 to 4 substituents independently chosen from C_1-C_4alkyl, (C_3-C_8cycloalkyl)C_0-C_2alkyl, phenylC_0-C_2alkyl and substituents that are taken together, with the carbon atom or carbon atoms to which they are bound to form a 3- to 7-membered cycloalkyl or a 4- to 7-membered heterocycloalkyl ring.


25. A compound or salt or hydrate thereof according to any one of claims 1-24, wherein Y is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, amino, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, and mono- or di-(C_1-C_6alkyl)amino.

26. A compound or salt or hydrate thereof according to any one of claims 1-25, wherein –W-X-Y is:

, , , ,

, , , ,

, , , or





;


wherein:


R_1 represents from 0 to 2 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, and mono- or di-(C_1-C_6alkyl)amino; and

Each R_5 is independently hydrogen, C_1-C_6alkyl, C_3-C_7cycloalkyl or phenyl; or taken together with another R_5 moiety and the carbon atom or carbon atoms to which they are bound to form a C_3-C_8cycloalkyl.

27. A compound or salt or hydrate thereof according to claim 27, wherein the compound has the formula:

, , , ,






or

;

wherein m is 0 or 1.

28. A compound of the formula:



or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Z_1, Z_2 and Z_3 are independently N, NH, CH, S or O; such that no more than one of Z_1, Z_2 and Z_3 is chosen from O and S;

W is $-C(=O)NR_4-$, $-NR_4C(=O)-$ or $-NR_4-NR_4-C(=O)-$;

V is C_1-C_6alkylene that is substituted with from 0 to 4 substituents independently chosen from: (i) C_1-C_4alkyl, (C_3-C_8cycloalkyl)C_0-C_2alkyl and phenylC_0-C_2alkyl; (ii) substituents that are taken together, with any intervening carbon atoms, to form a 3- to 7-membered cycloalkyl or a 4- to 7-membered heterocycloalkyl ring; and (iii) substituents that are taken together with R_4 and any intervening atoms to form a 4- to 7-membered heterocycloalkyl;

Y is C_3-C_{16}cycloalkyl, 6- to 16-membered aryl or 5- to 16-membered heteroaryl, each of which is substituted with from 0 to 6 substituents independently chosen from hydroxy, halogen, cyano, amino, nitro, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, C_1-C_6alkylsulfonyl, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

R_2 represents from 0 to 2 substituents independently chosen from halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-

C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

Each R_4 is independently hydrogen, C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_2alkyl or taken together with a substituent of V to form a 4- to 7-membered heterocycloalkyl;

Either:

(i) each R_5 is independently hydrogen, –COOH, C_1-C_6alkyl or (C_3-C_7cycloalkyl)C_0-C_4alkyl, such that at least one R_5 is not hydrogen; or

(ii) both R_5 moieties are taken together, with the carbon atom to which they are bound, to form a C_3-C_7cycloalkyl; and

R_A is a group of the formula -L-A-M, wherein:


L is absent or C_1-C_6alkylene that is optionally modified by the replacement of a carbon-carbon single bond with a double or triple carbon-carbon bond, which alkylene is optionally substituted with oxo, –COOH, $–SO_3H$, $–SO_2NH_2$, $–PO_3H_2$, tetrazole or oxadiazolone;

A is absent or CO, O, NR_6, S, SO, SO_2, $CONR_6$, (C_4-C_7cycloalkyl)C_0-C_2alkyl, or 4- to 7-membered heterocycloalkyl; wherein R_6 is hydrogen or C_1-C_6alkyl; and


M is a (5- to 10-membered heteroaryl)C_0-C_4alkyl that is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl, and 4- to 7-membered heterocycle;

such that R_A is not pyrrole.

29. A compound or salt or hydrate thereof according to claim 28, wherein the compound has the formula:



30. A compound or salt or hydrate thereof according to claim 29, wherein the compound has the formula:




or


;

wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

31. A compound or salt or hydrate thereof according to claim 28, wherein the compound has the formula:





32. A compound or salt or hydrate thereof according to claim 31, wherein the compound has the formula:



;

wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

33. A compound or salt or hydrate thereof according to claim 28, wherein the compound has the formula:

or ;

wherein R_3 is hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

34. A compound or salt or hydrate thereof according to any one of claims 30, 32 or 33, wherein each R_3 is independently hydrogen, halogen, C_1-C_4alkyl or C_1-C_4haloalkyl.


35. A compound or salt or hydrate thereof according to any one of claims 28-34, wherein R_A is (5- or 6-membered heteroaryl)C_0-C_4alkyl or (5- or 6-membered heteroaryl)C_0-C_4alkyl-T-, wherein T is S or O; each of which is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl and –COOH; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkenylthio, C_2-C_6alkyl ether, (mono- or di-C_1-C_6alkylamino)C_0-C_4alkyl, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, phenylC_0-C_4alkyl and (4- to 7-membered heterocycle)C_0-C_4alkyl; each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_4alkyl and C_1-C_4haloalkyl.

36. A compound or salt or hydrate thereof according to claim 35, wherein R_A is (5- or 6-membered heteroaryl)C_0-C_4alkyl that is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl, and 4- to 7-membered

heterocycle, wherein the 5- or 6-membered heteroaryl is pyridyl, pyrimidinyl, imidazolyl or chosen from:



37. A compound or salt or hydrate thereof according to any one of claims 28-36, wherein R_2 represents from 0 to 2 substituents independently chosen from halogen, C_1-C_6alkyl and C_1-C_6haloalkyl.



38. A compound or salt or hydrate thereof according to any one of claims 28-37, wherein V is methylene or ethylene, each of which is substituted with from 0 to 4 substituents independently chosen from C_1-C_4alkyl, (C_3-C_8cycloalkyl)C_0-C_2alkyl, phenylC_0-C_2alkyl and substituents that are taken together, with the carbon atom or carbon atoms to which they are bound, to form a 3- to 7-membered cycloalkyl or 4- to 7-membered heterocycloalkyl.

39. A compound or salt or hydrate thereof according to claim 38, wherein V is methylene.

40. A compound or salt or hydrate thereof according to any one of claims 28-39, wherein Y is C_3-C_{16}cycloalkyl, 6- to 10-membered aryl or 5- to 10-membered heteroaryl, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, amino, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, and mono- or di-(C_1-C_6alkyl)amino.

41. A compound or salt or hydrate thereof according to any one of claims 28-39, wherein Y is phenyl or a 5- or 6-membered heteroaryl; each of which is optionally fused to a 5- to 7-membered carbocycle or a 5- to 7-membered heterocycle; and each of which phenyl, heteroaryl, carbocycle and heterocycle is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, amino, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, and mono- or di-(C_1-C_6alkyl)amino.

42. A compound or salt or hydrate thereof according to any one of claims 28-41, wherein –W-V-C(R_5)(R_5)-Y is:

or ;

wherein:



is phenyl or a 5- or 6-membered heteroaryl;



R_1 represents from 0 to 2 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, and mono- or di-(C_1-C_6alkyl)amino; or two substituents represented by R_1 are taken together, with any intervening ring atoms, to form a fused 4- to 7-membered carbocycle or a fused 4- to 7-membered heterocycle;

Each R_5 is independently hydrogen, C_1-C_6alkyl, C_3-C_7cycloalkyl or phenyl; or both R_5 are taken together, with the carbon atom to which they are bound, to form a C_3-C_8cycloalkyl; and

Each R_{5a} is independently hydrogen, C_1-C_6alkyl, C_3-C_7cycloalkyl or phenyl; or both R_{5a} are taken together, with the carbon atom to which they are bound, to form a C_3-C_8cycloalkyl.

43. A compound or salt or hydrate thereof according to claim 42, wherein  is phenyl, pyridyl, pyrazolyl or pyrimidinyl.







44. A compound or salt or hydrate thereof according to claim 43, wherein –W-V-C(R_5)(R_5)-Y is:

or ;



wherein J and K are independently CH or N.

45. A compound or salt or hydrate thereof according to claim 44, wherein the compound has the formula:


,

,

,

,

or

;

wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

46. A compound of the formula:


or


or a pharmaceutically acceptable salt or hydrate thereof, wherein:

W is –C(=O)NR_4– or –NR_4C(=O) –;

X is C_2-C_6alkylene that is substituted with from 0 to 4 substituents independently chosen from:

(i) hydroxy and –COOH;

(ii) C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_6aminoalkyl, C_2-C_8alkyl ether, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl and phenylC_0-C_2alkyl;

(iii) substituents that are taken together, with any intervening carbon atoms, to form a 3- to 7-membered cycloalkyl or a 4- to 7-membered heterocycloalkyl; and

(iv) substituents that are taken together with R_4 and any intervening atoms to form a 4- to 7-membered heterocycloalkyl;

each of which (ii), (iii) and (iv) is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and 4- to 7-membered heterocycloalkyl;

Y is C_3-C_{16}cycloalkyl, phenyl or 6- to 10-membered heterocycle, each of which is substituted with from 0 to 6 substituents independently chosen from hydroxy, halogen, cyano, amino, nitro, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, C_1-C_6alkylsulfonyl, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

R_2 represents from 0 to 2 ring substituents independently chosen from halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

Each R_4 is independently hydrogen, C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_2alkyl or taken together with a substituent of X to form a 4- to 7-membered heterocycloalkyl;

R_A comprises a ring and has the formula -L-A-M, wherein:

L is absent or C_1-C_6alkylene that is optionally modified by the replacement of a carbon-carbon single bond with a double or triple carbon-carbon bond, which alkylene is optionally substituted with oxo,–COOH, $–SO_3H$, $–SO_2NH_2$, $–PO_3H_2$, tetrazole or oxadiazolone;

A is absent or CO, O, NR_6, S, SO, SO_2, $CONR_6$, NR_6CO, (C_4-C_7cycloalkyl)C_0-C_2alkyl, 4- to 7-membered heterocycloalkyl or 5- or 6-membered heteroaryl; wherein R_6 is hydrogen or C_1-C_6alkyl; and

M is:

(i) hydroxy, cyano, amino, halogen, aminocarbonyl, aminosulfonyl or –COOH; or





(ii) C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, (4- to 10-membered carbocycle)C_0-C_4alkyl, (4- to 7-membered heterocycle)C_0-C_4alkyl, C_1-C_6alkanoyloxy, C_1-C_6alkanoylamino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, C_1-C_6alkylsulfonyloxy, mono- or di-C_1-C_6alkylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, or mono- or di-(C_1-C_6alkyl)aminocarbonyl; each of which is substituted with from 0 to 4 substituents independently chosen from:

(a) oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl and –COOH; and

(b) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl, mono- or di-(C_1-C_6alkyl)aminoC_0-C_2alkyl, phenylC_0-C_2alkyl and (4- to 7-membered heterocycle)C_0-C_4alkyl; each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, C_1-C_4alkyl, C_2-C_4alkenyl and C_1-C_4haloalkyl;

such that R_A is not: (i) pyridazine that is substituted with C_1-C_6alkoxy, (ii) substituted or unsubstituted benzyl, (iii) unsubstituted phenyl or (iv) an O-linked moiety.

47. A compound or salt or hydrate thereof according to claim 46, wherein the compound has the formula:


,

,

or

;

wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

48. A compound or salt or hydrate thereof according to claim 47, wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-

C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, or mono- or di-(C_1-C_6alkyl)amino.

49. A compound or salt or hydrate thereof according to claim 48, wherein each R_3 is independently hydrogen, halogen, C_1-C_4alkyl or C_1-C_4haloalkyl.

50. A compound or salt or hydrate thereof according to any one of claims 46-49, wherein R_A is (5- or 6-membered heteroaryl)C_0-C_4alkyl that is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl and –COOH; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl and (4- to 7-membered heterocycle)C_0-C_2alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, C_1-C_4alkyl, C_2-C_4alkenyl and C_1-C_4haloalkyl.


51. A compound or salt or hydrate thereof according to claim 50, wherein the (5- or 6-membered heteroaryl)C_0-C_4alkyl is thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl or pyridazinyl.

52. A compound or salt or hydrate thereof according to any one of claims 46-51, wherein:

Y is phenyl or a 6-membered heteroaryl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, cyano, amino, nitro, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, C_1-C_6alkylsulfonyl, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino; and

R_4 is hydrogen or C_1-C_4alkyl.

53. A compound or salt or hydrate thereof according to claim 52, wherein –X-Y is:



;


wherein:

J and K are independently CH or N;


R_1 represents from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, and mono- or di-(C_1-C_6alkyl)amino; and

Each R_5 is independently hydrogen, C_1-C_6alkyl, C_3-C_7cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl, or taken together with another R_5 attached to the same carbon atom, and with the carbon atom to which the R_5 moieties are bound, to form a C_3-C_8cycloalkyl or 4- to 7-membered heterocycloalkyl.

54. A compound or salt or hydrate thereof according to claim 46, wherein the compound satisfies the formula:



or



wherein:

R_A is (5- or 6-membered heteroaryl)C_0-C_4alkyl that is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl and –COOH; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl and (4- to 7-membered heterocycle)C_0-C_2alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, C_1-C_4alkyl, C_2-C_4alkenyl and C_1-C_4haloalkyl;

J and K are independently CH or N;

R_1 represents from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, and mono- or di-(C_1-C_6alkyl)amino;


Each R_3 is independently hydrogen, halogen, C_1-C_4alkyl or C_1-C_4haloalkyl; and

Each R_5 is independently hydrogen, C_1-C_6alkyl, C_3-C_7cycloalkyl or phenyl; or two R_5 are taken together, with the carbon atom to which they are bound, to form a C_3-C_8cycloalkyl.

55. A compound or salt or hydrate thereof according to claim 54, wherein at least one R_5 is not hydrogen.

56. A compound or salt or hydrate thereof according to claim 55, wherein both R_5 are taken together, with the carbon atom to which they are bound, to form a C_3-C_8cycloalkyl.

57. A compound of the formula:



or a pharmaceutically acceptable salt or hydrate thereof, wherein:

W is $–C(=O)NR_4$-, $–NR_4C(=O)$- or $–NR_4$-NR_4-$C(=O)$-;

X is absent or C_1-C_6alkylene that is substituted with from 0 to 4 substituents independently chosen from: (i) hydroxy and –COOH;

(ii) C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_6aminoalkyl, C_2-C_8alkyl ether, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl and phenylC_0-C_2alkyl;

(iii) substituents that are taken together, with any intervening carbon atoms, to form a 3- to 7-membered cycloalkyl or a 4- to 7-membered heterocycloalkyl; and

(iv) substituents that are taken together with R_4 and any intervening atoms to form a 4- to 7-membered heterocycloalkyl;

each of which (ii), (iii) and (iv) is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and 4- to 7-membered heterocycloalkyl;

Y is C_3-C_{16}cycloalkyl, 6- to 16-membered aryl or 5- to 16-membered heteroaryl, each of which is substituted with from 0 to 6 substituents independently chosen from hydroxy, halogen, cyano, amino, nitro, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, C_1-C_6alkylsulfonyl, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

R_3 is hydrogen, halogen, cyano, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_2-C_6alkyl ether or (C_3-C_7cycloalkyl)C_0-C_4alkyl;

Each R_4 is independently hydrogen, C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_2alkyl or taken together with a substituent of X to form a 4- to 7-membered heterocycloalkyl; and


R_A is phenylC_0-C_4alkyl, (5- or 6-membered heterocycle)C_0-C_4alkyl, phenylC_0-C_2alkyl-T- or (5- or 6-membered heterocycle)C_0-C_4alkyl-T-, wherein T is S or O; each of which is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl and –COOH; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl and (4- to 7-membered heterocycle)C_0-C_2alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, C_1-C_4alkyl, C_2-C_4alkenyl and C_1-C_4haloalkyl.

58. A compound or salt or hydrate thereof according to claim 57, wherein R_3 is hydrogen, halogen, C_1-C_4alkyl or C_1-C_4haloalkyl.

59. A compound or salt or hydrate thereof according to claim 57 or claim 58, wherein –W-X-Y is:







wherein:

J and K are independently CH or N;

R_1 represents from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, and mono- or di-(C_1-C_6alkyl)amino; and

Each R_5 is independently hydrogen, C_1-C_6alkyl, C_3-C_7cycloalkyl. 4- to 7-membered heterocycloalkyl or phenyl; or taken together with another R_5 moiety and the carbon atom or carbon atoms to which they are bound to form a C_3-C_8cycloalkyl or 4- to 7-membered heterocycloalkyl.

60. A compound or salt or hydrate thereof according to claim 59, wherein –W-X-Y is:


,

,

or


61. A compound or salt or hydrate thereof according to claim 60, wherein at least one R_5 is not hydrogen.

62. A compound or salt or hydrate thereof according to claim 61, wherein both R_5 are taken together, with the carbon atom to which they are bound, to form a C_3-C_8cycloalkyl.

63. A compound or salt or hydrate thereof according to any one of claims 57-62, wherein R_A is phenyl or 5- or 6-membered heteroaryl, each of which is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, and halogen; and


(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)amino, and (4- to 7-membered heterocycle)C_0-C_2alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, C_1-C_4alkyl, C_2-C_4alkenyl and C_1-C_4haloalkyl.

64. A compound or salt or hydrate thereof according to any one of claims 57-62, wherein R_A is 5- to 7-membered heterocycloalkyl that is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, and halogen; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)amino, and (4- to 7-membered heterocycle)C_0-C_2alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, C_1-C_4alkyl, C_2-C_4alkenyl and C_1-C_4haloalkyl.


65. A compound or salt or hydrate thereof according to claim 57, wherein the compound has the formula:




wherein:

m is 0 or 1;

Y is:



or ;

J and K are independently CH or N;

R_1 represents from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, and mono- or di-(C_1-C_6alkyl)amino;

R_3 is hydrogen, halogen, C_1-C_4alkyl or C_1-C_4haloalkyl;


Each R_5 is independently (i) hydrogen; (ii) C_1-C_6alkyl, C_3-C_7cycloalkyl, 4- to 7-membered heterocycloalkyl or phenyl; or (iii) taken together with another R_5 moiety and the carbon atom to which they are bound to form a C_3-C_8cycloalkyl or 4- to 7-membered heterocycloalkyl; each of which (ii) or (iii) is substituted with from 0 to 3 substituents independently chose from hydroxy, halogen, amino, aminocarbonyl, C_1-C_6alkyl C_1-C_6alkoxy, mono- or di-(C_1-C_6alkyl)amino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, and 4- to 7-membered heterocycloalkyl; and

R_A is 5- to 7-membered heterocycloalkyl, phenyl or 5- or 6-membered heteroaryl, each of which is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, and halogen; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)amino, and (4- to 7-membered heterocycle)C_0-C_2alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, C_1-C_4alkyl, C_2-C_4alkenyl and C_1-C_4haloalkyl.

66. A compound of the formula:



or a pharmaceutically acceptable salt or hydrate thereof, wherein:



represents a 5-membered heteroaryl ring; such that 

is not furan, 1H-pyrrole or isoxazole;

W is –C(=O)NR_4–, –NR_4C(=O) – or –NR_4-NR_4-C(=O) –;

V is absent or C_1-C_5alkylene that is substituted with from 0 to 4 substituents independently chosen from: (i) –COOH, C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_6aminoalkyl, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl and phenylC_0-C_2alkyl; (ii) substituents that are taken together, with any intervening carbon atoms, to form a 3- to 7-membered cycloalkyl or a 4- to 7-membered heterocycloalkyl; and (iii) substituents that are taken together with R_4 and any intervening atoms to form a 4- to 7-membered heterocycloalkyl;

R_2 represents from 0 to 2 substituents independently chosen from halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

each R_4 is independently hydrogen, C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_2alkyl or taken together with a substituent of V to form a 4- to 7-membered heterocycloalkyl;

each R_5 is independently (i) –COOH; (ii) (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_6aminoalkyl, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl or phenylC_0-C_2alkyl; or (iii) taken together with another R_5 moiety and the carbon atom to which they are bound to form a C_3-C_8cycloalkyl or 4- to 7-

membered heterocycloalkyl; each of which (ii) or (iii) is substituted with from 0 to 3 substituents independently chose from hydroxy, halogen, amino, aminocarbonyl, C_1-C_6alkyl C_1-C_6alkoxy, mono- or di-(C_1-C_6alkyl)amino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, and 4- to 7-membered heterocycloalkyl; such that at least one R_5 is not methyl; and

R_{11} and R_{12} are

(i) independently chosen from C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl and (C_3-C_8cycloalkyl)C_0-C_2alkyl; or

(ii) taken together, with the nitrogen atom to which they are bound, to form a 4- to 7-membered heterocycloalkyl;

each of which (i) and (ii) is substituted with from 0 to 4 substituents independently chosen from hydroxy, halogen, cyano, amino, C_1-C_6alkyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl, and 4- to 7-membered heterocycle; and

R_A is a group of the formula -L-A-M, wherein:

L is absent or C_1-C_6alkylene that is optionally modified by the replacement of a carbon-carbon single bond with a double or triple carbon-carbon bond, which alkylene is optionally substituted with oxo, –COOH, $–SO_3H$, $–SO_2NH_2$, $–PO_3H_2$, tetrazole or oxadiazolone;

A is absent or CO, O, NR_6, S, SO, SO_2, $CONR_6$, NR_6CO, (C_4-C_7cycloalkyl)C_0-C_2alkyl, 4- to 7-membered heterocycloalkyl or 5- or 6-membered heteroaryl; wherein R_6 is hydrogen or C_1-C_6alkyl; and

M is:

(i) hydroxy, cyano, amino, aminocarbonyl, aminosulfonyl or –COOH; or

(ii) C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, (4- to 10-membered carbocycle)C_0-C_4alkyl, (4- to 10-membered heterocycle)C_0-C_4alkyl, C_1-C_6alkanoyloxy, C_1-C_6alkanoylamino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, C_1-C_6alkylsulfonyloxy, mono- or di-C_1-C_6alkylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, or mono- or di-(C_1-C_6alkyl)aminocarbonyl; each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-

C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl, and 4- to 7-membered heterocycle;

such that (i) R_A is not methyl, acetyl or trifluoroethanone; (ii) if 

is thiophene, then R_{11} and R_{12} not taken together to form morpholinyl; (iii) if 

is pyrazole, then R_A is not benzyl or 4-methylbenzyl; and (iv) if 


is thiazole, then R_A is not unsubstituted phenyl, unsubstituted pyridin-2-yl, unsubstituted thiophen-2-yl, unsubstituted thiophen-3-yl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl or 4-(p-tolyloxymethyl).

67. A compound or salt or hydrate thereof according to claim 66, wherein V is absent or methylene.

68. A compound or salt or hydrate thereof according to claim 66 or claim 67, wherein 


represents pyrazole, thiazole, imidazole, oxazole or thiophene.

69. A compound or salt or hydrate thereof according to any one of claims 66-68, wherein the compound satisfies the formula:





wherein Z_1, Z_2 and Z_3 are independently N, NH, CH, S or O; such that no more than one of Z_1, Z_2 and Z_3 is chosen from O and S.

70. A compound or salt or hydrate thereof according to claim 69, wherein the compound satisfies the formula:




71. A compound or salt or hydrate thereof according to claim 70, wherein the compound satisfies the formula:


or

;


wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

72. A compound or salt or hydrate thereof according to claim 71, wherein the compound satisfies the formula:




wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

73. A compound or salt or hydrate thereof according to claim 69, wherein the compound satisfies the formula:




or



wherein R_3 is hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

74. A compound or salt or hydrate thereof according to any one of claims 71-73, wherein each R_3 is independently hydrogen, halogen, C_1-C_4alkyl or C_1-C_4haloalkyl.

75. A compound or salt or hydrate thereof according to claim any one of claims 66-68, wherein the compound satisfies the formula:



wherein:

Z_4 and Z_5 are independently CH, N, NH, O or S; and

Z_6 is CH, S or O;

such that no more than one of Z_4, Z_5 and Z_6 is chosen from O and S.


76. A compound or salt or hydrate thereof according to any one of claims 66-75, wherein R_A is phenylC_0-C_2alkyl, (5- or 6-membered heteroaryl)C_0-C_4alkyl, phenylC_0-C_2alkyl-T- or (5- or 6-membered heteroaryl)C_0-C_4alkyl-T-, wherein T is S or O; each of which is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl and –COOH; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkenylthio, C_2-C_6alkyl ether, (mono- or di-C_1-C_6alkylamino)C_0-C_4alkyl, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-

(C_1-C_6alkyl)aminosulfonyl, and (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl; each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_4alkyl and C_1-C_4haloalkyl.

77. A compound or salt or hydrate thereof according to claim 75, wherein R_A is (5- or 6-membered heteroaryl)C_0-C_4alkyl that is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl, and 4- to 7-membered heterocycle; wherein the 5- or 6-membered heteroaryl is pyridyl, pyrimidinyl, imidazolyl or chosen from



78. A compound or salt or hydrate thereof according to any one of claims 66-75, wherein R_A is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkoxy, C_1-C_6alkylthio, C_2-C_6alkenylthio, C_2-C_6alkyl ether, C_1-C_6alkoxycarbonyl, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-C_1-C_6alkylaminosulfonyl, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl or (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl-T-, wherein T is S or O; each of which is substituted with from 0 to 4 substituents independently chosen from:


(i) oxo, amino, halogen, hydroxy, aminocarbonyl, aminosulfonyl and –COOH; and

(ii) C_1-C_6alkyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6alkylthio, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-C_1-C_6alkylaminocarbonyl, mono- or di-C_1-C_6alkylaminosulfonyl and 4- to 7-membered heterocycle; each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_4alkyl and C_1-C_4haloalkyl;

such that if  represents pyrazole or imidazole, then R_A is not optionally substituted C_1-C_6alkoxy.

79. A compound or salt or hydrate thereof according to claim 78, wherein R_A is C_1-C_6alkyl, C_2-C_6alkyl ether, C_1-C_4alkoxycarbonyl, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, or (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl; each of which is substituted with from 0 to 4 substituents independently chosen from amino, hydroxy, oxo, aminocarbonyl, aminosulfonyl, C_1-C_6alkyl, C_1-C_6hydroxyalkyl, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)amino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, 4- to 7-membered heterocycloalkyl, and 5- or 6-membered heteroaryl.

80. A compound or salt or hydrate thereof according to any one of claims 66-75, wherein R_A is a group of the formula:



wherein:

L is absent or C_1-C_6alkylene;



represents a 4- to 7-membered heterocycloalkyl that is optionally fused to phenyl or to a 6-membered heteroaryl; and


R_7 represents from 0 to 4 substituents independently chosen from:

(i) hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl and –COOH;

(ii) C_1-C_6alkyl, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, C_1-C_6alkylsulfonylC_0-C_4alkyl, C_1-C_6alkylsulfonylaminoC_0-C_4alkyl, and 4- to 7-membered heterocycle; each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6alkoxy, mono- or di-(C_1-C_6alkyl)amino, and C_1-C_6alkylsulfonylamino; and

(iii) substituents that are taken together to form a bridge of the Formula -$(CH_2)_q$-P-$(CH_2)_r$-, wherein q and r are independently 0 or 1 and P is CH_2, O, NH or S.

81. A compound or salt or hydrate thereof according to claim 80, wherein R_A is a group of the formula:



wherein:

G is CH or N;


s and t are independently 0, 1, 2, 3 or 4, such that the sum of s and t ranges from 2 to 5; and

R_8 is:

(i) hydrogen, aminocarbonyl, aminosulfonyl or –COOH; or

(ii) C_1-C_6alkyl, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, C_1-C_6alkylsulfonylC_0-C_4alkyl, C_1-C_6alkylsulfonylaminoC_0-C_4alkyl, or 4- to 7-membered heterocycle; each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6alkoxy, mono- or di-(C_1-C_6alkyl)amino, and C_1-C_6alkylsulfonylamino.

82. A compound or salt or hydrate thereof according to claim 81, wherein R_A is



or ;

wherein:

R_9 is: (i) C_1-C_6alkyl that is substituted with –COOH; or (ii) a 5- or 6-membered heteroaryl that is unsubstituted or substituted with 1 or 2 oxo; and

R_{10} represents one substituent chosen from:

(i) –COOH;


(ii) C_1-C_6alkyl that is substituted with –COOH;

(iii) mono- or di-(C_1-C_6alkyl)aminoC_0-C_2alkyl, C_1-C_6alkylsulfonyl and C_1-C_6alkylsulfonylamino; each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, oxo and –COOH; and


(iv) C_1-C_6haloalkylsulfonylamino.

83. A compound or salt or hydrate thereof according to any one of claims 66-82, wherein R_2 represents from 0 to 2 substituents independently chosen from halogen, C_1-C_6alkyl and C_1-C_6haloalkyl.

84. A compound or salt or hydrate thereof according to any one of claims 66-83, wherein



is: , , or




;

wherein:


R_{11} and R_{12} are taken together, with the nitrogen atom to which they are bound, to form a 4- to 7-membered heterocycloalkyl that is substituted with from 0 to 4 substituents independently chosen from hydroxy, halogen, cyano, amino, C_1-C_6alkyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl, and 4- to 7-membered heterocycle; and

Each R_5 is independently hydrogen, C_1-C_6alkyl, C_3-C_7cycloalkyl, 4- to 7-membered heterocycloalkyl or phenyl; or taken together with another R_5 moiety and the carbon atom or carbon atoms to which they are bound to form a C_3-C_8cycloalkyl or 4- to 7-membered heterocycloalkyl.


85. A compound or salt or hydrate thereof according to claim 84, wherein the compound has the formula:




,




,




,



,




or



; wherein m is 0 or 1.

86. A compound or salt or hydrate thereof according to claim 85, wherein the R_5 moieties are taken together, with the carbon atom to which they are bound, to form a C_3-C_8cycloalkyl.

87. A compound of the formula:



or a pharmaceutically acceptable salt or hydrate thereof, wherein:

W is $-C(=O)NR_4-$, $-NR_4C(=O)-$ or $-NR_4-NR_4-C(=O)-$;



is a 3- to 7-membered cycloalkyl or a 4- to 7-membered heterocycloalkyl;

Y is 5- to 7-membered heterocycloalkyl that is substituted with from 0 to 6 substituents independently chosen from hydroxy, halogen, cyano, amino, nitro, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, C_1-C_6alkylsulfonyl, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

R_3 is halogen, cyano, C_3-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, phenyl or 5- or 6-membered heteroaryl;

Each R_4 is independently hydrogen, C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_2alkyl or taken together with a substituent of X to form a 4- to 7-membered heterocycloalkyl; and

R_A is phenylC_0-C_4alkyl, (5- or 6-membered heterocycle)C_0-C_4alkyl, phenylC_0-C_2alkyl-T- or (5- or 6-membered heterocycle)C_0-C_4alkyl-T-, wherein T is S or O; each of which is substituted with from 0 to 4 substituents independently chosen from:


(i) oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl and –COOH; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl and (4- to 7-membered heterocycle)C_0-C_2alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, C_1-C_4alkyl, C_2-C_4alkenyl and C_1-C_4haloalkyl.

88. A compound or salt or hydrate thereof according to claim 87, wherein R_3 is halogen, cyano, C_1-C_4haloalkyl, phenyl or 5- or 6-membered heteroaryl.

89. A compound or salt or hydrate thereof according to claim 87 or claim 88, wherein Y is piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl, each of which is substituted with from 0 to 2 substituents independently chosen from C_1-C_6alkyl.




90. A compound or salt or hydrate thereof according to any one of claims 87-89, wherein:

Z is a group of the formula ;

x is 0, 1 or 2; and

M is CH_2, NH, S or O.

91. A compound or salt or hydrate thereof according to claim 90, wherein the compound has the formula:

,  or ;

wherein R_{13} is hydrogen or C_1-C_4alkyl.

92. A compound or salt or hydrate thereof according to any one of claims 87-81, wherein R_A is phenyl or 5- or 6-membered heteroaryl, each of which is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, and halogen; and


(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)amino, and (4- to 7-membered heterocycle)C_0-C_2alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, C_1-C_4alkyl, C_2-C_4alkenyl and C_1-C_4haloalkyl.

93. A compound or salt or hydrate thereof according to any one of claims 87-92, wherein R_A is 5- to 7-membered heterocycloalkyl that is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, and halogen; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)amino, and (4- to 7-membered heterocycle)C_0-C_2alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, C_1-C_4alkyl, C_2-C_4alkenyl and C_1-C_4haloalkyl.

94. A compound of the formula:



or a pharmaceutically acceptable salt or hydrate thereof, wherein:



represents a 5-membered heteroaryl ring; such that 

is not furan or isoxazole;

Y is 6- to 16-membered aryl or 5- to 16-membered heteroaryl, each of which is optionally substituted and each of which is preferably substituted with from 0 to 6 substituents independently chosen from hydroxy, halogen, cyano, amino, nitro, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, C_1-C_6alkylsulfonyl, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

R_2 represents from 0 to 2 substituents independently chosen from halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

R_A is a group of the formula -L-A-M, wherein:

L is absent or C_1-C_6alkylene that is optionally modified by the replacement of a carbon-carbon single bond with a double or triple carbon-carbon bond, which alkylene is optionally substituted with oxo, –COOH, $–SO_3H$, $–SO_2NH_2$, $–PO_3H_2$, tetrazole or oxadiazolone;

A is absent or CO, O, NR_6, S, SO, SO_2, $CONR_6$, NR_6CO, (C_4-C_7cycloalkyl)C_0-C_2alkyl, 4- to 7-membered heterocycloalkyl or 5- or 6-membered heteroaryl; wherein R_6 is hydrogen or C_1-C_6alkyl; and

M is:

(i) hydroxy, halogen, cyano, amino, aminocarbonyl, aminosulfonyl or –COOH; or

(ii) C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, (4- to 10-membered carbocycle)C_0-C_4alkyl, (4- to 10-membered heterocycle)C_0-C_4alkyl, C_1-C_6alkanoyloxy, C_1-C_6alkanoylamino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, C_1-C_6alkylsulfonyloxy, mono- or di-C_1-C_6alkylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, or mono- or di-(C_1-C_6alkyl)aminocarbonyl; each of which is optionally substituted and each of which is preferably substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, mono- or di-(C_1-C_6alkylamino)carbonyl, and 4- to 7-membered heterocycle;






such that (i) R_A is not methyl; and (ii) if 

is thiazole, then R_A is not unsubstituted phenyl or unsubstituted thiophen-3-yl.

95. A compound or salt or hydrate thereof according to any claim 94, wherein 

is pyrazole, thiazole, imidazole, oxazole or thiophene.

96. A compound or salt or hydrate thereof according to claim 65, wherein the compound satisfies the formula:


,

,

,

, or

;

wherein each R_3 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

97. A compound or salt or hydrate thereof according to claim 96, wherein each R_3 is independently hydrogen, halogen, C_1-C_4alkyl or C_1-C_4haloalkyl.


98. A compound or salt or hydrate thereof according to any one of claims 94-97, wherein R_A is phenylC_0-C_2alkyl, (5- or 6-membered heteroaryl)C_0-C_4alkyl, phenylC_0-C_2alkyl-T- or (5- or 6-membered heteroaryl)C_0-C_4alkyl-T-, wherein T is S or O; each of which is substituted with from 0 to 4 substituents independently chosen from:

(i) oxo, amino, halogen, hydroxy, cyano, aminocarbonyl, aminosulfonyl and –COOH; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkylthio, C_2-C_6alkenylthio, C_2-C_6alkyl ether, (mono- or di-C_1-

C_6alkylamino)C_0-C_4alkyl, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfonylamino, mono- or di-(C_1-C_6alkyl)aminosulfonyl, and (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, amino, oxo, aminocarbonyl, aminosulfonyl, –COOH, C_1-C_4alkyl and C_1-C_4haloalkyl.

99. A compound or salt or hydrate thereof according to any one of claims 94-98, wherein Y is:



;

J and K are independently CH or N; and

R_1 represents from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, and mono- or di-(C_1-C_6alkyl)amino.

100. A compound or pharmaceutically acceptable salt or hydrate thereof, wherein the compound is any one of compounds 1-321.

101. A compound or salt or hydrate thereof according to any one of claims 1-100, wherein the compound exhibits no detectable agonist activity an *in vitro* assay of $P2X_7$ receptor agonism.

102. A compound or salt or hydrate thereof according to any one of claims 1-101, wherein the compound is capable of exhibiting an IC_{50} value of 20 micromolar or less in an assay for $P2X_7$ receptor antagonism.

103. A pharmaceutical composition, comprising at least one compound or salt or hydrate thereof according to any one of claims 1-102 in combination with a physiologically acceptable carrier or excipient.

104. A pharmaceutical composition according to claim 103, wherein the composition is formulated as an injectible fluid, an aerosol, a cream, an oral liquid, a tablet, a gel, a pill, a capsule, a syrup, or a transdermal patch.

105. A method for modulating the activity of a $P2X_7$ receptor *in vitro*, the method comprising contacting $P2X_7$ receptor with at least one compound or salt or hydrate thereof

according to any one of claims 1-102, under conditions and in an amount sufficient to detectably alter $P2X_7$ receptor activity.

106. A method for modulating the activity of a $P2X_7$ receptor in a patient, comprising contacting cells expressing $P2X_7$ receptor with at least one compound or salt or hydrate thereof according to any one of claims 1-102, in an amount sufficient to detectably alter $P2X_7$ receptor activity *in vitro*, and thereby altering the activity of the $P2X_7$ receptor in the patient.

107. A method according to claim 106, wherein the patient is a human.

108. A method for treating a condition responsive to $P2X_7$ receptor modulation in a patient, comprising administering to the patient a therapeutically effective amount of at least one compound or salt or hydrate thereof according to any one of claims 1-102, and thereby alleviating the condition in the patient.

109. A method according to claim 108, wherein the condition is pain.

110. A method according to claim 109, wherein the pain is neuropathic pain.

111. A method according to claim 109, wherein the pain is arthritis-associated pain, a neuropathic pain syndrome, visceral pain, dental pain, headache, stump pain, meralgia paresthetica, burning-mouth syndrome, pain associated with nerve and root damage, causalgia, neuritis, neuronitis, neuralgia, surgery-related pain, musculoskeletal pain, central nervous system pain, spinal pain, Charcot's pains, ear pain, muscle pain, eye pain, orofacial pain, carpel tunnel syndrome, acute and chronic back pain, gout, scar pain, hemorrhoidal pain, dyspeptic pains, angina, nerve root pain, complex regional pain syndrome, cancer-associated pain, pain associated with venom exposure, trauma-associated pain, pain associated with autoimmune diseases or immunodeficiency disorders, or pain that results from hot flashes, burns, sunburn, or exposure to heat, cold or external chemical stimuli.

112. A method according to claim 108, wherein the condition is inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system disorder.

113. A method according to claim 108, wherein the condition is osteoarthritis, rheumatoid arthritis, arthrosclerosis, glaucoma, irritable bowel syndrome, inflammatory bowel disease, cirrhosis, lupus, scleroderma, Alzheimer's disease, traumatic brain injury, asthma, chronic obstructive pulmonary disease, or interstitial fibrosis.

114. A method for inhibiting death of retinal ganglion cells in a patient, comprising administering to the patient a therapeutically effective amount of at least one compound or salt or hydrate thereof according to any one of claims 1-102, and thereby inhibiting death of retinal ganglion cells in the patient.

115. A method for promoting weight loss in a patient, comprising administering to the patient a therapeutically effective amount of at least one $P2X_7$ receptor antagonist, and thereby promoting weight loss in the patient.

116. A method according to any one of claims 102-115, wherein the patient is a human.

117. A compound or salt or hydrate thereof according to any one of claims 1-102, wherein the compound is radiolabeled.

118. A method for determining the presence or absence of $P2X_7$ receptor in a sample, comprising the steps of:

(a) contacting a sample with a compound or salt or hydrate thereof according to any one of claims 1-102, under conditions that permit modulation by the compound of $P2X_7$ receptor activity; and

(b) detecting a signal indicative of a level of the compound or salt or hydrate thereof modulating $P2X_7$ receptor activity, and therefrom determining the presence or absence of $P2X_7$ receptor in the sample.

119. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 103 in a container; and

(b) instructions for using the composition to treat pain.

120. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 103 in a container; and

(b) instructions for using the composition to treat inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder, obesity or an immune system disorder.






121. The use of a compound or salt or hydrate thereof according to any one of claims 1-102 for the manufacture of a medicament for the treatment of a condition responsive to $P2X_7$ receptor modulation.

122. A use according to claim 121, wherein the condition is pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, osteoarthritis, rheumatoid arthritis, arthrosclerosis, glaucoma, irritable bowel syndrome, inflammatory

bowel disease, Alzheimer's disease, traumatic brain injury, asthma, chronic obstructive pulmonary disease, cirrhosis, lupus, scleroderma, or interstitial fibrosis.

CLAIMS

1. A compound of the formula:


,

,

;

or

;

W is $-C(=O)NR_4-$, $-NR_4C(=O)-$ or $-NR_4\text{-}NR_4\text{-}C(=O)-$;

V is C_1-C_6alkylene that is substituted with from 0 to 4 substituents independently chosen from: (i) C_1-C_4alkyl, (C_3-C_8cycloalkyl)C_0-C_2alkyl and phenylC_0-C_2alkyl; (ii) substituents that are taken together, with any intervening carbon atoms, to form a 3- to 7-membered cycloalkyl or a 4- to 7-membered heterocycloalkyl ring; and (iii) substituents that are taken together with R_4 and any intervening atoms to form a 4- to 7-membered heterocycloalkyl;

Y is phenyl or 5- to 6-membered heteroaryl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, cyano, amino, nitro, oxo, aminocarbonyl, aminosulfonyl, -COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, C_1-C_6alkylsulfonyl, (C_3-C_7cycloalkyl)C_0-C_4alkyl and mono- or di-(C_1-C_6alkyl)amino;

R_2 represents from 0 to 2 substituents independently chosen from halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, -COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl and (C_1-C_6alkyl)sulfonylamino;

Each R_4 hydrogen or C_1-C_4alkyl;


Either:


(i) each R_5 is independently hydrogen, -COOH, C_1-C_6alkyl or (C_3-C_7cycloalkyl)C_0-C_4alkyl, such that at least one R_5 is not hydrogen; or


(ii) both R_5 moieties are taken together, with the carbon atom to which they are bound, to form a C_3-C_7cycloalkyl; and

R_A is phenyl or 5-6 membered heteroaryl that is substituted with from 0 to 4 substituents independently chosen from oxo, amino, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)amino.

2. A compound or salt or hydrate thereof according to claim 1, wherein the compound has the formula:




,


or


;

wherein each R_2 is independently hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, -COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

3. A compound or salt or hydrate thereof according to claim 1, wherein the compound has the formula:




;


wherein R_2 is hydrogen, halogen, cyano, amino, nitro, aminocarbonyl, aminosulfonyl, -COOH, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, (C_3-C_7cycloalkyl)C_0-C_4alkyl, mono- or di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, C_1-C_6alkanoylamino, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminosulfonyl or (C_1-C_6alkyl)sulfonylamino.

4. A compound or salt or hydrate thereof according to any one of claims 1-3, wherein Y is C_3-C_{16}cycloalkyl, 6- to 10-membered aryl or 5- to 10-membered heteroaryl, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, amino, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6alkoxy, and mono- or di-(C_1-C_6alkyl)amino.

5. A compound or salt or hydrate thereof according to any one of claims 1-3, wherein Y is phenyl or a 5- or 6-membered heteroaryl; each of which is optionally fused to a 5- to 7-membered carbocycle or a 5- to 7-membered heterocycle; and each of which phenyl, heteroaryl, carbocycle and heterocycle is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, amino, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6alkoxy, and mono- or di-(C1-C6alkyl)amino.

6. A compound or salt or hydrate thereof according to claim 1, wherein -W-V-C(R5)(R5)-Y is:



or


;

wherein J and K are independently CH or N.

7. The compound of claim 1 selected from the group consisting of:

1-(4-amino-5-methylpyrimidin-2-yl)-N-[2-(4-chlorophenyl)-4-methylpentyl]-3-methyl-1 H-pyrazole-4-carboxamide;

1-(4-amino-5-fluoropyrimidin-2-yl)-N-[2-(4-chlorophenyl)-4-methylpentyl]-3-methyl-1 H-pyrazole-4-carboxamide;

N-[2-(4-chlorophenyl)-4-methylpentyl]-1-(5-fluoropyrimidin-2-yl)-3-methyl-1H-pyrazole-4-carboxamide;

1-(4-amino-5-methylpyrimidin-2-yl)-3-methyl-N-14-ethyl-2-[4-(trifluoromethyl)phenyl]pentyl}-1H-pyrazole-4-carboxamide;

1-(4-amino-5-fluoropyrimidin-2-yl)-3-methyl-N-{4-ethyl-2-[4-(trifluoromethyl)phenyl]pentyl}-1H-pyrazole-4-carboxamide;

1-(5-fluoropyrimidin-2-yl)-3-methyl-N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-1 H-pyrazole-4-carboxamide;

1-(4-amino-5-fluoropyrimidin-2-yl)-N-{[1-(6-methylpyridin-3-yl)cyclohexyl]methyl}-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(4-amino-5-fluoropyrimidin-2-yl)-N-(4-methyl-2-pyridin-3-ylpentyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(4-amino-5-fluoropyrimidin-2-yl)-N-[2-(4-chlorophenyl)-4-methylpentyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(4-amino-5-fluoropyrimidin-2-yl)-N-{[1-(4-chlorophenyl)cyclohexyl]methyl}-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(4-amino-5-fluoropyrimidin-2-yl)-N-[2-(4-chlorophenyl)propyl]-3-(trifluoromethyl)-1 H-pyrazole-4-carboxamide;

1-(4-amino-5-fluoropyrimidin-2-yl)-N-[2-(4-chlorophenyl)pentyl]-3-(trifluoromethyl)-1 H-pyrazole-4-carboxamide;

N-[(1-pyridin-3-ylcyclohexyl)methyl]-1-pyrimidin-2-yl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(5-fluoropyrimidin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1 H-pyrazole-4-carboxamide;

1-(4-aminopyrimidin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1 H-pyrazole-4-carboxamide;

1-(4-amino-5-methylpyrimidin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(3-aminopyrazin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

N- {[1-(6-methylpyridin-3-yl)cyclohexyl]methyl}-2-pyrimidin-2-yl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide;

N-[2-(4-chlorophenyl)pentyl]-2-pyrimidin-2-yl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide;

N-[(1-pyridin-3-ylcyclohexyl)methyl]-2-pyrimidin-2-yl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide;

2-pyridin-3-yl-N-[(1-pyridin-3-ylcyclohexyl)methyl]-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide;

N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-2-pyridin-3-yl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide;

4-ethyl-2-pyridin-3-yl-N-[(1-pyridin-3-ylcyclohexyl)methyl]-1,3-thiazole-5-carboxamide;

1-(4-amino-5-fluoropyrimidin-2-yl)-N-{[1-(4-chlorophenyl)cyclobutyl]methyl}-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(4-amino-5-fluoropyrimidin-2-yl)-N-{[1-(4-methoxyphenyl)cyclohexyl]methyl}-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(4-amino-5-methylpyrimidin-2-yl)-3-methyl-N-({1-[4-(trifluoromethyl)phenyl]cyclohexyl}methyl)-1 H-pyrazole-4-carboxamide;

1-(4-amino-5-methylpyrimidin-2-yl)-N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(4-amino-5-methylpyrimidin-2-yl)-3-(trifluoromethyl)-N-({1-[4-(trifluoromethyl)phenyl]cyclohexyl}methyl)-1H-pyrazole-4-carboxamide;

1-(4-aminopyrimidin-2-yl)-3-methyl-N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-1 H-pyrazole-4-carboxamide;

3-methyl-N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-1-pyrazin-2-yl-1H-pyrazole-4-carboxamide;

1-(4-aminopyrimidin-2-yl)-3-methyl-N-({1 -[4-(trifluoromethyl)phenyl]cyclohexyl}methyl)-1H-pyrazole-4-carboxamide;

1-(4-amino-5-methylpyrimidin-2-yl)-3-tert-butyl-N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-1H-pyrazole-4-carboxamide;

1-(4-amino-5-methylpyrimidin-2-yl)-3-tert-butyl-N-({1-[4-(trifluoromethyl)phenyl]cyclohexyl}methyl)-1H-pyrazole-4-carboxamide;

3-methyl-N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-1-pyrimidin-2-yl-1 H-pyrazole-4-carboxamide;

1-(3-aminopyrazin-2-yl)-3-methyl-N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-1 H-pyrazole-4-carboxamide;

1-(6-aminopyrazin-2-yl)-3-methyl-N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-1 H-pyrazole-4-carboxamide;

3-methyl-1-pyrimidin-2-yl-N-({1-[4-(trifluoromethyl)phenyl]cyclohexyl}methyl)-1H-pyrazole-4-carboxamide;

1-(3-aminopyrazin-2-yl)-3-methyl-N-({1-[4-(trifluoromethyl)phenyl]cyclohexyl}methyl)-1H-pyrazole-4-carboxamide;

1-(6-aminopyrazin-2-yl)-3-methyl-N-({1-[4-(trifluoromethyl)phenyl] cyclohexyl}methyl)-1H-pyrazole-4-carboxamide;

3-methyl-1-pyrazin-2-yl-N-({1-[4-(trifluoromethyl)phenyl]cyclohexyl}methyl)-1H-pyrazole-4-carboxamide;

1-(4-methoxypyrimidin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1 H-pyrazole-4-carboxamide;

1-(3-methylpyrazin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

N-(2-adamantan-1-yl-2-hydroxyethyl)-1-(4-amino-5-fluoropyrimidin-2-yl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(6-methylpyrazin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(3-ethylpyrazin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(3,6-dimethylpyrazin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1 H-pyrazole-4-carboxamide;

1-(4-amino-5-methylpyrimidin-2-yl)-N-{[1-(4-fluorophenyl)cyclohexyl]methyl}-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-(5-methoxypyrimidin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1 H-pyrazole-4-carboxamide;

1-(5-chloropyrimidin-2-yl)-N-[(1-pyridin-3-ylcyclohexyl)methyl]-3-(trifluoromethyl)-1 H-pyrazole-4-carboxamide;

N- {[1-(4-chlorophenyl)cyclohexyl]methyl}-1-pyrimidin-2-yl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

1-pyrimidin-2-yl-3-(trifluoromethyl)-N-({1-[4-(trifluoromethyl)phenyl]cyclohexyl}methyl)-1H-pyrazole-4-carboxamide;

N-{[4-(4-chlorophenyl)tetrahydro-2H-pyran-4-yl]methyl}-1-pyrimidin-2-yl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

N-{[1-(4-methoxyphenyl)cyclohexyl]methyl}-1-pyrimidin-2-yl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-1-pyrimidin-2-yl-3-(trifluoromethyl)-1 H-pyrazole-4-carboxamide;

N-[2-(4-chlorophenyl)pentyl]-1-pyrimidin-2-yl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

N-[2-(4-chlorophenyl)propyl]-1-pyrimidin-2-yl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

N-(4-methyl-2-pyridin-3-ylpentyl)-1-pyrimidin-2-yl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

N-{[1-(4-chlorophenyl)cyclobutyl]methyl}-1-pyrimidin-2-yl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide ;

4-ethyl-N-[(1-pyridin-3-ylcyclohexyl)methyl]-2-pyrimidin-2-yl-1,3-thiazole-5-carboxamide; and

4-ethyl-N-{4-methyl-2-[4-(trifluoromethyl)phenyl]pentyl}-2-pyrimidin-2-yl-1,3-thiazole-5-carboxamide.

8. A pharmaceutical composition, comprising at least one compound or salt or hydrate thereof according to any one of claims 1-7 in combination with a physiologically acceptable carrier or excipient.

9. Use of a compound or salt or hydrate thereof according to any one of claims 1-7 in the manufacture of a medicament for the treatment of a condition responsive to P2X7 receptor modulation.

10. The use according to claim 9, wherein the condition is pain, inflammation, a neurological or neurodegenerative disorder, a centrally-mediated neuropsychiatric disorder, a cardiovascular disorder, osteoarthritis, rheumatoid arthritis, arthrosclerosis, glaucoma, irritable bowel syndrome, inflammatory bowel disease, Alzheimer's disease, traumatic brain injury, asthma, chronic obstructive pulmonary disease, cirrhosis, lupus, scleroderma, or interstitial fibrosis.

11. The use according to claim 9, wherein the pain is arthritis-associated pain, a neuropathic pain syndrome, visceral pain, dental pain, headache, stump pain, meralgia paresthetica, burning-mouth syndrome, pain associated with nerve and root damage, causalgia, neuritis, neuronitis, neuralgia, surgery-related pain, musculoskeletal pain, central nervous system pain, spinal pain, Charcot's pains, ear pain, muscle pain, eye pain, orofacial pain, carpel tunnel syndrome, acute and chronic back pain, gout, scar pain, hemorrhoidal pain, dyspeptic pains, angina, nerve root pain, complex regional pain syndrome, cancer-associated pain, pain associated with venom exposure, trauma-associated pain, pain associated with autoimmune diseases or immunodeficiency disorders, or pain that results from hot flashes, bums, sunburn, or exposure to heat, cold or external chemical stimuli.

12. The use according to claim 9, wherein the centrally-mediated neuropsychiatric disorder is depression, depression mania, bipolar disease, anxiety, schizophrenia, an eating disorder, a sleep disorder or a cognition disorder.

13 The use according to claim 9, wherein the neurological disorder is epilepsy.

14. The compound of claim 1 wherein the compound is N-[2-(4-chlorophenyl)-2-morpholin-4-ylethyl]-2-pyrimidin-2-yl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide.